Drugs / Senl-T7
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| — | NCT05626400 | Aug 2022 → Oct 2027 expected | T lymphoblastic leukemia/lymphoma | Hebei Senlang Biotechnology Inc., Ltd. | Recruiting | No outcome recorded |
| — | NCT04916860 | Jan 2021 → Jan 2023 | T-cell childhood acute lymphocytic leukemia | Hebei Senlang Biotechnology Inc., Ltd. | Unknown | No outcome recorded |
| — | NCT04928105 | Jan 2021 → Jan 2023 | T-cell non-Hodgkin lymphoma | Hebei Senlang Biotechnology Inc., Ltd. | Unknown | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SenL-T7 | “Clinical Study of SenL-T7 CAR T Cells in the Treatment of Relapsed and Refractory CD7+ T-cell Lymphoblastic Leukemia or T-cell Lymphoblastic Lymphoma” NCT04916860 ↗ |
| Action | Deplete | “CD7 CAR-T cells” NCT04928105 ↗ |
| Modality | Cell therapy | “anti CD7 CAR-T cell” NCT04916860 ↗ |
| Target | CD7 | “CD7 CAR-T cells” NCT04928105 ↗ |